ES2183140T3 - Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa. - Google Patents

Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa.

Info

Publication number
ES2183140T3
ES2183140T3 ES97907545T ES97907545T ES2183140T3 ES 2183140 T3 ES2183140 T3 ES 2183140T3 ES 97907545 T ES97907545 T ES 97907545T ES 97907545 T ES97907545 T ES 97907545T ES 2183140 T3 ES2183140 T3 ES 2183140T3
Authority
ES
Spain
Prior art keywords
inhibitor
hydrolasses
leucotrene
cycloxygenasa
immunosuppressor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97907545T
Other languages
English (en)
Spanish (es)
Inventor
Susan A Gregory
Peter C Isakson
Gary Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2183140T3 publication Critical patent/ES2183140T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES97907545T 1996-02-13 1997-02-11 Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa. Expired - Lifetime ES2183140T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60065596A 1996-02-13 1996-02-13

Publications (1)

Publication Number Publication Date
ES2183140T3 true ES2183140T3 (es) 2003-03-16

Family

ID=24404526

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97907545T Expired - Lifetime ES2183140T3 (es) 1996-02-13 1997-02-11 Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa.

Country Status (11)

Country Link
US (3) US6407140B1 (https=)
EP (1) EP0880363B1 (https=)
JP (1) JP2001506574A (https=)
AT (1) ATE223732T1 (https=)
AU (1) AU1952597A (https=)
CA (1) CA2246336A1 (https=)
DE (1) DE69715382T2 (https=)
DK (1) DK0880363T3 (https=)
ES (1) ES2183140T3 (https=)
PT (1) PT880363E (https=)
WO (1) WO1997029774A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029776A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
AU1952597A (en) * 1996-02-13 1997-09-02 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
HUP0302068A3 (en) * 2000-07-20 2005-05-30 Lauras As Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
EP1442027A1 (en) 2001-10-09 2004-08-04 3-Dimensional Pharmaceuticals, Inc. Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes
US20040146503A1 (en) * 2002-08-28 2004-07-29 Tesi Raymond J. Methods and compositions for inducing stable immune tolerance
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
AR055054A1 (es) * 2005-04-22 2007-08-01 Wyeth Corp Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina
AT502258B1 (de) * 2005-07-22 2007-09-15 Univ Wien Cox-i-inhibitorverbindungen
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
WO2007079078A1 (en) * 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Diamine derivatives as inhibitors of leukotriene a4 hydrolase
AR069126A1 (es) 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
SI2336125T1 (sl) 2008-04-11 2013-04-30 Janssen Pharmaceutica N.V. Tiazolopiridin-2-iloksi-fenil in tiazolopirazin-2-iloksi-fenil amini kot modulatorji levkotrien a4 hidrolaze
CN102459251B (zh) 2009-05-14 2015-05-20 詹森药业有限公司 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
ES2864862T3 (es) 2013-03-12 2021-10-14 Celltaxis Llc Métodos de inhibición de la leucotrieno A4 hidrolasa
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
RU2678196C2 (ru) 2013-03-14 2019-01-24 Селтакссис, Инк. Производные 2-фениламино-3-цианопиразоло[1,5-а]пиримидина, полезные в качестве ингибитора лейкотриен-a4-гидролазы
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
MX385718B (es) 2016-06-13 2025-03-18 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
EP3801559B1 (en) 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
EP3911647B1 (en) 2019-01-15 2023-12-13 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196839A (ja) 1983-04-21 1984-11-08 Sankyo Co Ltd フエニル酢酸誘導体
US4873259A (en) 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5242940A (en) 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US5234950A (en) 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
GB8927287D0 (en) 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
US5220059A (en) 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
JPH0819069B2 (ja) 1990-07-25 1996-02-28 アボツト・ラボラトリーズ リポキシゲナーゼ阻害活性を有するアセチレン誘導体
IE913655A1 (en) 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
CA2099868C (en) 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
GB9215921D0 (en) 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
US5354865A (en) 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
US5288751A (en) 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0764644A1 (en) 1993-01-15 1997-03-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a gastrointestinal condition
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6718494A (en) 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5298521A (en) 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
ES2141916T3 (es) 1993-11-30 2000-04-01 Searle & Co Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion.
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
CA2246356A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
AU1952597A (en) * 1996-02-13 1997-09-02 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor

Also Published As

Publication number Publication date
CA2246336A1 (en) 1997-08-21
US20050043355A1 (en) 2005-02-24
DE69715382D1 (de) 2002-10-17
ATE223732T1 (de) 2002-09-15
DK0880363T3 (da) 2003-01-20
WO1997029774A1 (en) 1997-08-21
JP2001506574A (ja) 2001-05-22
DE69715382T2 (de) 2003-04-30
EP0880363A1 (en) 1998-12-02
PT880363E (pt) 2002-12-31
US20030004191A1 (en) 2003-01-02
US6407140B1 (en) 2002-06-18
AU1952597A (en) 1997-09-02
EP0880363B1 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
ES2183140T3 (es) Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa.
ES2162937T3 (es) Preparado combinado para su aplicacion en enfermedades inmunologicas.
DE69526206D1 (de) Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit
DE69129332D1 (de) Behandlung von organtransplantatsabstossung
ES2154299T3 (es) Metodos para la regulacion de la motilidad gastrointestinal.
DE59911542D1 (de) Mischungen enthaltend thermoplastisches Polyurethan
PT831882E (pt) Composicoes de segmentos de fibra de colagenio reconstituido e metodos de preparacao das mesmas
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
BG102690A (en) Il-8 receptor antagonists
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
MX9306960A (es) Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion.
DK0517797T3 (da) Anvendelse af D-vitaminanaloger i behandlingen af akne
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
EA200000506A1 (ru) Состав для снижения веса
DK0869970T3 (da) Endothelcelleprolifereringsinhibitor og dens anvendelse
FR2700472B1 (fr) Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
ES2116411T3 (es) La sal sulfato de un triazol sustituido, composiciones farmaceuticas de la misma y su uso en terapia
ES2078904T3 (es) Nuevos derivados de neplanocina.
DE69625230D1 (de) Thrombininhibitoren
KR900017595A (ko) 면역억제 방법
ES2171226T3 (es) Composicion para el tratamiento de los lechos para aves de corral.
FR2702147B1 (fr) Inhibiteur de l'activite collagenase et composition cosmetique renfermant un tel inhibiteur.
ES2094930T3 (es) Nueva proteina inhibidora de trombina aislada de garrapatas.
ES2148753T3 (es) Sal de metilpirrolidinilindol.
NO20016326D0 (no) Anvendelse av proteinet UK 114 for å hindre avstötning av organtransplantatet